GlassScriptPhysician profile
David J Winchester
NPI 1023122595
$2,446.93
in general payments reported to CMS, 2019-2025
38 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2023: $850 · 2024: $633 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821 · Travel and Lodging: $446 · Education: $58.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.79 |
| Travel and Lodging | $445.55 |
| Education | $58.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elucent Medical | $634.55 | 2023 | |
| Novartis Pharmaceuticals Corporation | $235.60 | 2023-2025 | |
| Janssen Biotech, INC. | $152.20 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Pacira Pharmaceuticals Incorporated | $121.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.18 | 2024-2025 | Fruzaqla, Vpriv |
| Astrazeneca Pharmaceuticals LP | $96.12 | 2024-2025 | Enhertu, Farxiga |
| Genentech USA, INC. | $95.94 | 2024-2025 | Phesgo, Columvi, Polivy |
| Mirati Therapeutics, INC. | $65.86 | 2023 | Krazati |
| Daiichi Sankyo INC. | $64.25 | 2025 | Injectafer, Enhertu |
| Tersera Therapeutics LLC | $58.76 | 2024-2025 | Xermelo, Quzyttir |
| Legend Biotech USA INC. | $48.28 | 2025 | Carvykti |
| Amgen INC. | $47.66 | 2023-2024 | Lumakras, Otezla, Repatha |
| Eisai INC. | $46.34 | 2024 | |
| Incyte Corporation | $44.44 | 2023-2025 | Jakafi |
| Adaptive Biotechnologies Corporation | $43.48 | 2024-2025 | Clonoseq |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $41.69 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $41.16 | 2024 | Lynparza, Keytruda, Capvaxive |
| Gilead Sciences, INC. | $36.25 | 2024-2025 | Trodelvy |
| Astellas Pharma US INC | $34.87 | 2024 | Xospata |
| Springworks Therapeutics, INC. | $34.75 | 2024 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $31.51 | 2025 | Pyrukynd |
| Kite Pharma, INC. | $30.54 | 2025 | Yescarta |
| Stemline Therapeutics INC. | $28.48 | 2025 | Orserdu |
| Glaxosmithkline, LLC. | $26.90 | 2024 | Jemperli, Zejula |
| Deciphera Pharmaceuticals INC. | $26.80 | 2025 | Qinlock, Romvimza |
| Novocure INC. | $24.52 | 2025 | Optune Lua (Novottf-200t) |
| E.R. Squibb & Sons, L.L.C. | $23.91 | 2023 | |
| Seagen INC. | $22.33 | 2023 | Adcetris |
| Melinta Therapeutics, LLC | $20.10 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Tempus Ai, INC | $19.78 | 2025 | Xt Cdx |
| Acrotech Biopharma INC. | $19.63 | 2025 | Beleodaq |
| Bayer Healthcare Pharmaceuticals INC. | $19.11 | 2024 | |
| Syndax Pharmaceuticals, INC. | $18.73 | 2025 | |
| Alnylam Pharmaceuticals INC. | $17.52 | 2025 | Givlaari |
| Pfizer INC. | $17.41 | 2024 | |
| Exact Sciences Corporation | $16.69 | 2023 | Cologuard Collection Kit |
| Emd Serono, INC. | $16.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Winchester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.